Trending NewsTrending NewsNASDAQ:NVAX Novavax (NVAX) Stock Price, News & Analysis $8.37 -0.41 (-4.67%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$8.38 +0.01 (+0.06%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Novavax Stock (NASDAQ:NVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Novavax alerts:Sign Up Key Stats Today's Range$8.28▼$9.1350-Day Range$6.30▼$8.7852-Week Range$5.01▼$15.22Volume9.97 million shsAverage Volume7.09 million shsMarket Capitalization$1.36 billionP/E Ratio3.67Dividend YieldN/APrice Target$15.86Consensus RatingHold Company Overview Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Read More Novavax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreNVAX MarketRank™: Novavax scored higher than 94% of companies evaluated by MarketBeat, and ranked 60th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingNovavax has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 4 buy ratings, 2 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNovavax has only been the subject of 3 research reports in the past 90 days.Read more about Novavax's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Novavax are expected to grow in the coming year, from ($1.46) to $0.08 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is 3.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is 3.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.77.Price to Earnings Growth RatioNovavax has a PEG Ratio of 0.10. PEG Ratios below 1 indicate that a company could be undervalued. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted26.52% of the outstanding shares of Novavax have been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Novavax has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.27 Percentage of Shares Shorted26.52% of the outstanding shares of Novavax have been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Novavax has recently decreased by 7.47%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News Sentiment0.64 News SentimentNovavax has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Novavax this week, compared to 11 articles on an average week.Search Interest39 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 105% compared to the previous 30 days.MarketBeat Follows9 people have added Novavax to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.00% of the stock of Novavax is held by insiders.Percentage Held by Institutions53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Novavax's insider trading history. Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Email Address NVAX Stock News HeadlinesNovavax Stock Surges Amid Strategic GainsAugust 10 at 2:43 AM | msn.comFDA reinstates top vaccines regulator just days after his abrupt departureAugust 9 at 8:41 PM | msn.comAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scrambling to buy gold coins and bars. But some savvy investors have used a different way to profit from gold bull runs — a special investment with a long history of making 13 times … 21 times … 157 times … even a surprising 1,000 times more than physical gold.August 10 at 2:00 AM | Weiss Ratings (Ad)Brokerages Set Novavax, Inc. (NASDAQ:NVAX) PT at $15.86August 9 at 2:21 AM | americanbankingnews.comTD Cowen Reaffirms Their Hold Rating on Novavax (NVAX)August 8 at 4:05 PM | theglobeandmail.comNovavax (NASDAQ:NVAX) Trading 14.6% Higher Following Strong EarningsAugust 8 at 3:47 AM | americanbankingnews.comNovavax (NASDAQ:NVAX) Shares Gap Up on Earnings BeatAugust 8 at 2:45 AM | americanbankingnews.comNovavax, Inc. (NASDAQ:NVAX) Q2 2025 Earnings Call TranscriptAugust 7 at 10:55 AM | msn.comSee More Headlines NVAX Stock Analysis - Frequently Asked Questions How have NVAX shares performed this year? Novavax's stock was trading at $8.04 on January 1st, 2025. Since then, NVAX stock has increased by 4.1% and is now trading at $8.37. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings results on Wednesday, August, 6th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.69. The business's revenue was down 42.4% compared to the same quarter last year. Read the conference call transcript. When did Novavax's stock split? Novavax shares reverse split on Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Who are Novavax's major shareholders? Top institutional investors of Novavax include Shah Capital Management (7.11%), Geode Capital Management LLC (2.33%), SG Americas Securities LLC (0.56%) and Jupiter Asset Management Ltd. (0.54%). Insiders that own company stock include James F Young, Filip Dubovsky, Rachel K King and Gregory M Glenn. View institutional ownership trends. How do I buy shares of Novavax? Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA). Company Calendar Last Earnings8/06/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:NVAX CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees1,990Year Founded1987Price Target and Rating Average Price Target for Novavax$15.86 High Price Target$26.00 Low Price Target$6.00 Potential Upside/Downside+89.5%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$2.28 Trailing P/E Ratio3.67 Forward P/E RatioN/A P/E Growth0.1Net Income-$187.50 million Net Margins39.20% Pretax Margin39.99% Return on Equity-142.33% Return on Assets28.65% Debt Debt-to-Equity Ratio5.93 Current Ratio2.36 Quick Ratio2.03 Sales & Book Value Annual Sales$682.16 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book36.39Miscellaneous Outstanding Shares162,420,000Free Float160,798,000Market Cap$1.36 billion OptionableOptionable Beta2.50 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NVAX) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.